EGFR and non-small cell lung carcinoma: The third-generation EGFR TKI osimertinib is currently considered to be the gold standard therapy in naïve EGFR-mutant NSCLC, in light of its further prolongation of overall survival, better toxicity profile, and higher intracranial activity compared with other EGFR TKIs [6].